Apoptotic markers in cancer

被引:107
作者
Holdenrieder, S [1 ]
Stieber, P [1 ]
机构
[1] Univ Hosp Munich Grosshadern, Inst Clin Chem, D-81377 Munich, Germany
关键词
cell death; apoptosis; cancer; tumor; diagnosis; prognosis; therapy; monitoring; prediction; sFas; CD95; cytokeratins; CYFRA; 21-1; TPA; TPS; DNA; nucleosomes;
D O I
10.1016/j.clinbiochem.2004.05.003
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
In cancer, apoptotic processes occur both spontaneously and induced by antitumor therapies. Qualitative and quantitative changes in cancer cell death along with proliferative alterations are essential determinants in the pathogenesis and progression of malignant disease and its responsiveness to therapy. Besides detecting apoptosis by invasive means in tumor tissue, apoptotic products can be quantified in the circulation. Although circulating apoptotic products usually lack organ and tumor specificity, they contribute in the assessment of disease extent or aggressiveness. The ease of drawing blood facilitates the serial measurement of circulating apoptotic markers to monitor antitumor treatment and predict early response to therapy. This review describes the features of apoptotic and necrotic cell death along with the role the balance between the rates of cell death and cell proliferation plays in the progression of malignancy. The intracellular pathways mediating apoptosis are next summarized. The focus then shifts to the apoptotic markers found in the circulation and their diagnostic, prognostic, predictive, and management utility in cancer. (C) 2004 The Canadian Society of Clinical Chemists. All rights reserved.
引用
收藏
页码:605 / 617
页数:13
相关论文
共 192 条
[31]   Apoptosis in human disease: A new skin for the old ceremony? [J].
Fadeel, B ;
Orrenius, S ;
Zhivotovsky, B .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1999, 266 (03) :699-717
[32]  
FADOK VA, 1992, J IMMUNOL, V148, P2207
[33]  
Flemming W., 1885, Archiv fuer Anatomie und Physiologie (Anat), P221
[34]   PLASMA DNA AS A MARKER OF CANCEROUS CELL-DEATH - INVESTIGATIONS IN PATIENTS SUFFERING FROM LUNG-CANCER AND IN NUDE-MICE BEARING HUMAN TUMORS [J].
FOURNIE, GJ ;
COURTIN, JP ;
LAVAL, F ;
CHALE, JJ ;
POURRAT, JP ;
PUJAZON, MC ;
LAUQUE, D ;
CARLES, P .
CANCER LETTERS, 1995, 91 (02) :221-227
[35]  
Giovanella L, 1995, Q J Nucl Med, V39, P285
[36]   Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: Comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA) [J].
Giovanella, L ;
Ceriani, L ;
Giardina, G ;
Bardelli, D ;
Tanzi, F ;
Garancini, S .
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2002, 40 (03) :298-303
[37]   Immunoassay of neuron-specific enolase (NSE) and serum fragments of cytokeratin 19 (CYFRA 21.1) as tumor markers in small cell lung cancer: Clinical evaluation and biological hypothesis [J].
Giovanella, L ;
Piantanida, R ;
Ceriani, L ;
Bandera, M ;
Novario, R ;
Bianchi, L ;
Roncari, G .
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 1997, 12 (01) :22-26
[38]   CELL DEATHS IN NORMAL VERTEBRATE ONTOGENY [J].
GLUCKSMANN, A .
BIOLOGICAL REVIEWS OF THE CAMBRIDGE PHILOSOPHICAL SOCIETY, 1951, 26 (01) :59-86
[39]   Cell death inhibition: Keeping caspases in check [J].
Goyal, L .
CELL, 2001, 104 (06) :805-808
[40]  
GRAEPER L, 1914, ARCH ZELLFORSCH, V12, P373